Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54%GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestitureConference call begins at 4:30 p.m. Eastern time todayBOTH ...

Strategic divestiture heightens focus on proprietary, higher-margin cell processing productsAll-cash transaction fortifies balance sheetBOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approxi ...

BOTHELL, Wash., Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's fina ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has BioLife Solutions, Inc. (BLFS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BioLife Solutions, Inc. is one of 1019 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank in ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten – Lake Street Capital Markets Operator Good afternoon, and welcome to the BioLife Solutions Q2 2024 Shareholder and A ...

Table of Contents ____________________________________________________ Title of each class Trading symbol Name of exchange on which registered Common stock, par value $0.001 per share BLFS The NASDAQ Stock Market, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ____________________________________________________ FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUA ...

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 57.14%. A quarter ago, it was expected that this company would post a loss of $0.26 per share when it actually produced a loss of $0.19, delivering a surprise of 26.92%. Over the last four quarters, the company ha ...

3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Second Quarter 2024 Financial Results Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing re ...

Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife S ...